What question did this study set out to answer?

To determine whether relative interleukin-10 deficiency contributes to psoriasis pathogenesis and evaluate the therapeutic efficacy of subcutaneous interleukin-10 administration.

February 15, 1998Journal of Clinical InvestigationOpen Access

IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.

View Full Paper

Ask AI

Bookmark

Authors

KAK. AsadullahUniversity of Potsdam WSWolfram SterryCentre National de la Recherche Scientifique KSK. StephanekHumboldt-Universität zu Berlin

Discussion

Member takes

Implication

Phase 2 pilot trial demonstrates clinical improvement and immune suppression with interleukin-10 in psoriasis, indicating a novel therapeutic pathway.

Key Points

To determine whether relative interleukin-10 deficiency contributes to psoriasis pathogenesis and evaluate the therapeutic efficacy of subcutaneous interleukin-10 administration.
Assessed cutaneous and peripheral blood mononuclear cell IL-10 mRNA expression in psoriasis patients before and during standard antipsoriatic therapy.
Conducted an open-label phase 2 pilot trial evaluating daily subcutaneous IL-10 administration (8 µg/kg/d) over 24 days in three patients (N=3).
Psoriasis lesions exhibited a relative deficiency in cutaneous IL-10 mRNA expression compared with other inflammatory dermatoses, which normalized during established antipsoriatic therapy.
Subcutaneous IL-10 treatment yielded clinical improvement along with suppressed monocytic HLA-DR expression, decreased TNF-α and IL-12 secretion, and reduced plasma IL-12 levels.
IL-10 administration stimulated a shift toward type 2 cytokine profiles, increasing IL-4-, IL-5-, and IL-10-producing T cells, serum IgE levels, and intracutaneous IL-10 mRNA expression.

Cite This Study

Asadullah et al. (1998) studied this question.

synapsesocial.com/papers/6a7146a58031ec7bb1dcdd71 https://doi.org/10.1172/jci1476

View Full Paper

Ask AI

Bookmark

Implication

Phase 2 pilot trial demonstrates clinical improvement and immune suppression with interleukin-10 in psoriasis, indicating a novel therapeutic pathway.

IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.

Discussion

Member takes

Implication

Key Points

Cite This Study

IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider